SCHEMBL30170535

SCHEMBL30170535

CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.42
OPRD1 P41143 4/20 0.42
OPRK1 P41145 2/20 0.42
FOLH1 Q04609 3/20 0.42
CTSB P07858 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
TASP1 Q9H6P5 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
FURIN P09958 1/20 0.38
KEAP1 Q14145 2/20 0.38
GLO1 Q04760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29485672 0.94 FOLH1 (0.48) OPRM1OPRD1OPRK1FOLH1CTSB
SCHEMBL30170575 0.93 OPRM1 (0.40) OPRM1OPRD1OPRK1FOLH1CTSB
SCHEMBL30170446 0.91 EGFR (0.44) FOLH1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30170441 0.91 GLO1 (0.44) OPRK1FOLH1GRIN2DGRIN3BGRIN1
SCHEMBL30170524 0.91 GLO1 (0.44) OPRK1FOLH1GRIN2DGRIN3BGRIN1
SCHEMBL30844024 0.91 FOLH1 (0.45) OPRM1OPRD1OPRK1FOLH1CTSB
SCHEMBL29485686 0.90 GRIN2D (0.46) FOLH1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29564468 0.89 FOLH1 (0.50) FOLH1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29421985 0.88 KEAP1 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31073601 0.88 GRIN2D (0.47) FOLH1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149851-A2 METHODS FOR TREATING INFLAMMATORY DISEASES YUYU PHARMA, INC. (KR) 2025-07-17 WO claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US claimed
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU PHARMA, INC. (KR) 2023-05-11 US claimed
EP-4114430-A2 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU Pharma, Inc. (KR) 2023-01-11 EP claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-20230312648-A1 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES YUYU PHARMA, INC. (KR) 2023-10-05 US disclosed
US-11613558-B2 Peptides and pharmaceutical compositions for treating eye diseases YUYU PHARMA, INC. (KR) 2023-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312648-A1 PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES VIP, IAPP, SCTR OPRM1 4327/4885OPRD1 3721/4885OPRK1 3035/4885
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS VIP, TSLP, IAPP OPRM1 2446/4885OPRD1 2266/4885OPRK1 1141/4885
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient VIP, IAPP, NGLY1 OPRM1 4589/4885OPRD1 3752/4885OPRK1 3957/4885
US-11613558-B2 Peptides and pharmaceutical compositions for treating eye diseases VIP, IAPP, SCTR OPRM1 4327/4885OPRD1 3721/4885OPRK1 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.